Peptide receptor radionuclide therapy
J Hofland, T Brabander, FA Verburg… - The Journal of …, 2022 - academic.oup.com
The concept of using a targeting molecule labeled with a diagnostic radionuclide for using
positron emission tomography or single photon emission computed tomography imaging …
positron emission tomography or single photon emission computed tomography imaging …
[HTML][HTML] Optimising radioligand therapy for patients with gastro-entero-pancreatic neuroendocrine tumours: expert opinion from an Italian Multidisciplinary Group
Radioligand therapy (RLT) with lutetium (177Lu) oxodotreotide is an approved therapy in
combination with somatostatin analogues (SSAs) for patients with advanced, well …
combination with somatostatin analogues (SSAs) for patients with advanced, well …
[HTML][HTML] PET criteria by cancer type from imaging interpretation to treatment response assessment: beyond FDG PET score
F Dondi, A Lazzarato, J Gorica, P Guglielmo, F Borgia… - Life, 2023 - mdpi.com
Background: in recent years, the role of positron emission tomography (PET) and
PET/computed tomography (PET/CT) has emerged as a reliable diagnostic tool in a wide …
PET/computed tomography (PET/CT) has emerged as a reliable diagnostic tool in a wide …
Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary …
R Gallicchio, A Giordano, M Milella, R Storto… - Cancer …, 2023 - journals.sagepub.com
Background We retrospectively aimed to assess the prognostic significance of somatostatin
receptor (SSTR) standardized uptake value (SUVmaxsstr), SSTR representative tumor …
receptor (SSTR) standardized uptake value (SUVmaxsstr), SSTR representative tumor …
Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross …
Purpose The immune environment represents a new, but little explored, tool for
understanding neuroendocrine neoplasms (NENs) behavior. An immunosuppressed …
understanding neuroendocrine neoplasms (NENs) behavior. An immunosuppressed …
[HTML][HTML] PD-L1 expression, tumor-infiltrating lymphocytes, and mismatch repair proteins status in digestive neuroendocrine neoplasms: exploring their potential role as …
E Multone, S La Rosa, C Sempoux, S Uccella - Virchows Archiv, 2024 - Springer
Theragnostic biomarkers are still needed to select patients with digestive neuroendocrine
neoplasms (NENs) for an optimal management. The PD-1/PD-L1 pathway plays a pivotal …
neoplasms (NENs) for an optimal management. The PD-1/PD-L1 pathway plays a pivotal …
[HTML][HTML] Endocrine and Neuroendocrine Tumors: A Special Issue
A Berruti, V Amoroso, N Fazio - Cancers, 2022 - mdpi.com
Endocrine and neuroendocrine tumors (NETs) represent a group of heterogeneous
malignancies that have endocrine cell onset as a common denominator. They are relatively …
malignancies that have endocrine cell onset as a common denominator. They are relatively …
La valutazione della risposta alla terapia con radioligandi nei tumori neuroendocrini gastroenteropancreatici
V Liberini, R Laudicella, M Balma, S Peano, A Muni… - L'Endocrinologo, 2024 - Springer
La terapia con radioligandi (Radioligand therapy, RLT, o Peptide Receptor Radionuclide
Therapy, PRRT) è una delle opzioni terapeutiche più efficaci per i tumori neuroendocrini …
Therapy, PRRT) è una delle opzioni terapeutiche più efficaci per i tumori neuroendocrini …